Citi maintains 'Hold' rating on Myriad Genetics Inc (Nasdaq: MYGN). Price target $50.

Citi analyst says, "We believe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE